Next-Generation Anti–HER2-Antibody Drug Conjugates: Extending the Actionability to “HER2-Low” Breast Cancer
IJMS | Free Full-Text | Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors | HTML
Novel Agents and Strategies Under Evaluation for Patients with HER2-Positive mBC
PowerPoint プレゼンテーション
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape - ESMO Open
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | NEJM
Spotlight on Trastuzumab Deruxtecan for HER2-mutation NSCLC | LCTT
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial - The Lancet Oncology
Strategic Collaboration in Oncology Trastuzumab Deruxtecan (DS-8201)
ds8201 - Twitter Search / Twitter
Antitumor immunity caused by combination of DS-8201a and anti-CTLA-4... | Download Scientific Diagram
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study - The Lancet ...
Study of Targeted Therapy for HER2-Positive Metastatic Breast Cancer - YouTube
Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond | SpringerLink
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | NEJM
Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response Rates and Disease Control Rates » ADC Review
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology
Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model | PLOS ONE
Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review
Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant Benefit for HER2+ Breast Cancer Patients Pretreated with Ado-trastuzumab Emtansine » ADC Review
The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers - Annals of Oncology
